Skip to content

house · Committee report

H. Rept. 118-549

REAL-TIME BENEFIT TOOL IMPLEMENTATION ACT

2024-06-11

Committees

Associated legislation

Text

Background

H.R. 7512 was introduced on March 1, 2024, and was referred to the Committee on Energy and Commerce and the Committee on Ways and Means. Committee Hearings The Committee on Ways and Means held the following hearing(s) concerning the policy in H.R. 7512: On May 16, 2023, the Committee on Ways and Means held a hearing titled, ``Hearing on Health Care Price Transparency: A Patient's Right to Know'' to examine how a lack of transparency in America's health care system increases costs and prevents patients from being effective health care shoppers.

Committee Action

The Committee on Ways and Means marked up H.R. 7512, the Real-Time Benefit Tool Implementation Act, on March 6, 2024, and favorably reported the bill, as amended, to the House of Representatives (with quorum being present). D. Designated Hearing Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop and consider H.R. 7512: ``Hearing on Health Care Price Transparency: A Patient's Right to Know'' May 16, 2023. II. EXPLANATION OF THE BILL A. Reasons for Change As part of the Consolidated Appropriations Act of 2020, Congress codified a requirement for Medicare Part D PDPs to support prescriber real-time benefit tools. The Centers for Medicare and Medicaid Services has not implemented the program in the 3 years since the bill passed. This bill will place a firm implementation date of January 1, 2027 to ensure the program is implemented. B. Explanation of Provisions Sec. 1. Short title The title of the bill is the Real Time Benefit Tools Implementation Act. Sec. 2. Ensuring implementation of real-time benefit tools under Part D of the Medicare program Provides an implementation date of no later than January 1, 2027 for Medicare Part D real time benefit tools. C. Effective Date The bill would become effective January 1, 2027. III. VOTES OF THE COMMITTEE In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 7512, ``The Real-Time Benefit Tool Implementation Act,'' on March 6, 2024. H.R. 7512 was ordered favorably reported to the House of Representatives as amended by a roll call vote of 42 yeas to 0 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... X ...... ......... Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... X ...... ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... X ...... ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... ......... Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... X ...... ......... Mr. Beyer............ ...... ...... ......... Mr. Kustoff........................ X ...... ......... Mr. Evans............ X ...... ......... Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... X ...... ......... Mr. Moore.......................... X ...... ......... Mrs. Steel......................... X ...... ......... Ms. Van Duyne...................... X ...... ......... Mr. Feenstra....................... X ...... ......... Ms. Malliotakis.................... X ...... ......... Mr. Carey.......................... X ...... ......... ---------------------------------------------------------------------------------------------------------------- IV. BUDGET EFFECTS OF THE BILL A. Committee Estimate of Budgetary Effects With respect to clause 3(d) of rule XIII of the Rules of the House of Representatives, a cost estimate provided by the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not made available to the Committee in time for the filing of this report. B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee states that the bill involved no new or increased budget authority. The Committee states further that the bill involves no new or increased tax expenditures. V. COST ESTIMATE PREPARED BY THE CONGRESSIONAL BUDGET OFFICE With respect to the requirements of clause 3(c)(2) of rule XIII of the Rules of the House of Representatives and section 308(a) of the Congressional Budget Act of 1974 and with respect to requirements of clause (3)(c)(3) of rule XIII of the Rules of the House of Representatives and section 402 of the Congressional Budget Act of 1974, the Committee has requested but not received a cost estimate for this bill from the Director of Congressional Budget Office. The Chairman of the Committee shall cause such estimate and statement to be printed in the Congressional Record upon its receipt by the Committee. VI. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE A. Committee Oversight Findings and Recommendations With respect to clause 3(c)(1) of rule XIII of the Rules of the House of Representatives, the Committee made findings and recommendations that are reflected in this report. B. Statement of General Performance Goals and Objectives With respect to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee advises that the bill does not authority funding, so no statement of general performance goals and objectives is required. C. Information Relating to Unfunded Mandates This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104- 4). The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits With respect to clause 9 of rule XXI of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill, and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. E. Duplication of Federal Programs In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report from the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139; or (3) a program related to a program identified in the most recent Catalog of Federal Domestic Assistance, published pursuant to the Federal Program Information Act (Pub. L. No. 95-220, as amended by Pub. L. No. 98-169). VII. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows. Section 1860D-4(o) of the Social Security Act is amended by striking paragraph (1) and inserting the following: ``(1) In general.--Not later than January 1, 2027, a PDP sponsor of a prescription drug plan shall implement one or more electronic real-time benefit tools that meet the requirements described in paragraph (2).'' Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (new matter is printed in italics and existing law in which no change is proposed is shown in roman): SOCIAL SECURITY ACT * * * * * * * TITLE XVIII--HEALTH INSURANCE FOR THE AGED AND DISABLED * * * * * * * Part D--Voluntary Prescription Drug Benefit Program Subpart 1--Part D Eligible Individuals and Prescription Drug Benefits * * * * * * * beneficiary protections for qualified prescription drug coverage Sec. 1860D-4. (a) Dissemination of Information.-- (1) General information.-- (A) Application of ma information.--A PDP sponsor shall disclose, in a clear, accurate, and standardized form to each enrollee with a prescription drug plan offered by the sponsor under this part at the time of enrollment and at least annually thereafter, the information described in section 1852(c)(1) relating to such plan, insofar as the Secretary determines appropriate with respect to benefits provided under this part, and, subject to subparagraph (C), including the information described in subparagraph (B). (B) Drug specific information.--The information described in this subparagraph is information concerning the following: (i) Access to specific covered part D drugs, including access through pharmacy networks. (ii) How any formulary (including any tiered formulary structure) used by the sponsor functions, including a description of how a part D eligible individual may obtain information on the formulary consistent with paragraph (3). (iii) Beneficiary cost-sharing requirements and how a part D eligible individual may obtain information on such requirements, including tiered or other copayment level applicable to each drug (or class of drugs), consistent with paragraph (3). (iv) The medication therapy management program required under subsection (c). (v) The drug management program for at-risk beneficiaries under subsection (c)(5). (vi) For plan year 2021 and each subsequent plan year, subject to subparagraph (C), with respect to the treatment of pain-- (I) the risks associated with prolonged opioid use; and (II) coverage of nonpharmacological therapies, devices, and nonopioid medications-- (aa) in the case of an MA-PD plan under part C, under such plan; and (bb) in the case of a prescription drug plan, under such plan and under parts A and B. (C) Targeted provision of information.--A PDP sponsor of a prescription drug plan may, in lieu of disclosing the information described in subparagraph (B)(vi) to each enrollee under the plan, disclose such information through mail or electronic communications to a subset of enrollees under the plan, such as enrollees who have been prescribed an opioid in the previous 2-year period. (2) Disclosure upon request of general coverage, utilization, and grievance information.--Upon request of a part D eligible individual who is eligible to enroll in a prescription drug plan, the PDP sponsor offering such plan shall provide information similar (as determined by the Secretary) to the information described in subparagraphs (A), (B), and (C) of section 1852(c)(2) to such individual. (3) Provision of specific information.-- (A) Response to beneficiary questions.--Each PDP sponsor offering a prescription drug plan shall have a mechanism for providing specific information on a timely basis to enrollees upon request. Such mechanism shall include access to information through the use of a toll-free telephone number and, upon request, the provision of such information in writing. (B) Availability of information on changes in formulary through the internet.--A PDP sponsor offering a prescription drug plan shall make available on a timely basis through an Internet website information on specific changes in the formulary under the plan (including changes to tiered or preferred status of covered part D drugs). (4) Claims information.--A PDP sponsor offering a prescription drug plan must furnish to each enrollee in a form easily understandable to such enrollees-- (A) an explanation of benefits (in accordance with section 1806(a) or in a comparable manner); and (B) when prescription drug benefits are provided under this part, a notice of the benefits in relation to-- (i) for a year preceding 2025, the initial coverage limit for the current year; and (ii) the annual out-of-pocket threshold for the current year. Notices under subparagraph (B) need not be provided more often than as specified by the Secretary and notices under subparagraph (B)(ii) shall take into account the application of section 1860D-2(b)(4)(C) to the extent practicable, as specified by the Secretary. (b) Access to Covered Part D Drugs.-- (1) Assuring pharmacy access.-- (A) Participation of any willing pharmacy.--A prescription drug plan shall permit the participation of any pharmacy that meets the terms and conditions under the plan. (B) Discounts allowed for network pharmacies.--For covered part D drugs dispensed through in-network pharmacies, a prescription drug plan may, notwithstanding subparagraph (A), reduce coinsurance or copayments for part D eligible individuals enrolled in the plan below the level otherwise required. In no case shall such a reduction result in an increase in payments made by the Secretary under section 1860D-15 to a plan. (C) Convenient access for network pharmacies.-- (i) In general.--The PDP sponsor of the prescription drug plan shall secure the participation in its network of a sufficient number of pharmacies that dispense (other than by mail order) drugs directly to patients to ensure convenient access (consistent with rules established by the Secretary). (ii) Application of tricare standards.--The Secretary shall establish rules for convenient access to in-network pharmacies under this subparagraph that are no less favorable to enrollees than the rules for convenient access to pharmacies included in the statement of work of solicitation (#MDA906-03-R-0002) of the Department of Defense under the TRICARE Retail Pharmacy (TRRx) as of March 13, 2003. (iii) Adequate emergency access.-- Such rules shall include adequate emergency access for enrollees. (iv) Convenient access in long-term care facilities.--Such rules may include standards with respect to access for enrollees who are residing in long-term care facilities and for pharmacies operated by the Indian Health Service, Indian tribes and tribal organizations, and urban Indian organizations (as defined in section 4 of the Indian Health Care Improvement Act). (D) Level playing field.--Such a sponsor shall permit enrollees to receive benefits (which may include a 90-day supply of drugs or biologicals) through a pharmacy (other than a mail order pharmacy), with any differential in charge paid by such enrollees. (E) Not required to accept insurance risk.-- The terms and conditions under subparagraph (A)

Source: https://api.congress.gov/v3/committee-report/118/hrpt/549